- Conditions
- Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Interventions
- VB119
- Drug
- Lead sponsor
- Tenet Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced May 21, 2026, 11:10 PM EDT